Technicals - Good breakout on increasing volume - early days, page-126

’for nothing’????? I presume you don’t realise that LBT has $10m Cash at Bank, has spent $40m+ on R&D with a massive global partner to create a first to market product that is FDA and EU approved for the two massive markets in the world.

They have successfully launched a number of Centres of Excellence sites with global labs that have praised the product, to the extent they are first purchasers.

Even with conservative sales estimates LBT’s Shaw is APAS sales revenue has a NPV of well over $150m.

it’s purely a matter of when they finalise the current negotiations with the “global” distributor. Once announced cannot see this below 50c